Osteoporosis & bone health

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

BMJPublished Systematic review, network meta-analysis and meta-regression analysis of randomised clinical trials

Authors' conclusion

The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators.

Study context

Population
Non-Asian postmenopausal women, no age restriction; RCTs published 1 January 1996 to 24 November 2021
Participants
>80,000 women69 trials
Comparison
Osteoporosis treatments vs placebo or active comparator
Outcome
Clinical fractures

Pooled result

As reported in the abstract

Odds ratio (95% CI)
Bisphosphonatesvs Parathyroid hormone receptor agonistsbisphosphonates less effective
1.49(1.12–2.00)
Denosumabvs Parathyroid hormone receptor agonistsdenosumab less effective
1.85(1.18–2.92)
Denosumabvs Romosozumabdenosumab less effective
1.56(1.02–2.39)

Further pooled results

Outcomeβ (95% CI)
Clinical fractures vs placebo with increasing mean age (antiresorptive treatments, meta-regression)17 studies; greater reduction with increasing mean age0.98 (0.96–0.99)

Vertebral fractures

Effect of all treatments vs placebo
Denosumab, PTH receptor agonists and romosozumab more effective than oral bisphosphonates

Clinical fractures vs placebo with increasing mean age (antiresorptive treatments, meta-regression)

Effect of all treatments otherwise unaffected by baseline risk indicators

Safety

No harm outcomes were seen

Original publication

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. Published 2 May 2023. doi:10.1136/bmj-2021-068033

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.